{
  "meta": {
    "disclaimer": "Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. We may limit or otherwise restrict your access to the API in line with our Terms of Service.",
    "terms": "https://open.fda.gov/terms/",
    "license": "https://open.fda.gov/license/",
    "last_updated": "2026-09-29",
    "results": {
      "skip": 0,
      "limit": 1,
      "total": 1
    }
  },
  "results": [
    {
      "product_ndc": "0002-3977",
      "generic_name": "selpercatinib",
      "labeler_name": "Eli Lilly and Company",
      "brand_name": "RETEVMO",
      "active_ingredients": [
        {
          "name": "SELPERCATINIB",
          "strength": "40 mg/1"
        }
      ],
      "finished": true,
      "packaging": [
        {
          "package_ndc": "0002-3977-60",
          "description": "60 CAPSULE in 1 BOTTLE (0002-3977-60)",
          "marketing_start_date": "20200508",
          "sample": false
        }
      ],
      "listing_expiration_date": "20271231",
      "openfda": {},
      "marketing_category": "NDA",
      "dosage_form": "CAPSULE",
      "spl_id": "7481a510-805c-4f99-b6ae-7b44e70f5f55",
      "product_type": "HUMAN PRESCRIPTION DRUG",
      "route": [
        "ORAL"
      ],
      "marketing_start_date": "20200508",
      "product_id": "0002-3977_7481a510-805c-4f99-b6ae-7b44e70f5f55",
      "application_number": "NDA213246",
      "brand_name_base": "RETEVMO",
      "pharm_class": [
        "Breast Cancer Resistance Protein Inhibitors [MoA]",
        "Cytochrome P450 2C8 Inhibitors [MoA]",
        "Cytochrome P450 3A Inhibitors [MoA]",
        "Kinase Inhibitor [EPC]",
        "Multidrug and Toxin Extrusion Transporter 1 Inhibitors [MoA]",
        "P-Glycoprotein Inhibitors [MoA]",
        "Rearranged during Transfection (RET) Inhibitors [MoA]"
      ]
    }
  ]
}